Published in Medical Letter on the CDC and FDA, February 5th, 2006
Emergo Group will assist with Bio-Matrix' Quality Management System (QSR) prior to registration with the U.S. Food and Drug Administration (FDA) for production of medical devices and stem cell banking activities. Bio-Matrix will also meet ISO 13485:2003 requirements.
Emergo senior VP Ian Gordon notes, "Bio-Matrix has demonstrated their dedication to process control and they understand the advantages of implementing a quality...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA